A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
Public ClinicalTrials.gov record NCT04948554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
Study identification
- NCT ID
- NCT04948554
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Enrollment
- 5 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2023
- Primary completion
- Oct 17, 2023
- Completion
- Oct 17, 2023
- Last update posted
- Nov 23, 2023
2023
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Altman Clinical and Translational Research Institute (Site 1013) | La Jolla | California | 92037-0943 | — |
| Keck Medical Center ( Site 1001) | Los Angeles | California | 90033 | — |
| Georgetown University Medical Center ( Site 1010) | Washington D.C. | District of Columbia | 20007 | — |
| University of Florida ( Site 1002) | Gainesville | Florida | 32610 | — |
| Central Florida Pulmonary Group ( Site 1005) | Orlando | Florida | 32803 | — |
| Medster Research, LLC ( Site 1017) | Valdosta | Georgia | 31605-1096 | — |
| University of Kansas Medical Center ( Site 1007) | Kansas City | Kansas | 66160 | — |
| The Cleveland Clinic Foundation ( Site 1003) | Cleveland | Ohio | 44195 | — |
| Penn State Milton S Hershey Medical Center ( Site 1004) | Hershey | Pennsylvania | 17033 | — |
| West Tennessee Research Institute ( Site 1012) | Jackson | Tennessee | 38305 | — |
| Metroplex Clinical Research Center ( Site 1018) | Dallas | Texas | 75231-4446 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04948554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04948554 live on ClinicalTrials.gov.